The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Leading pharmaceutical and IT companies have said they will quit Ireland if a proposed ban on so-called forever chemicals is ...

Pfizer is set to raise £2.5bn by selling a 7.7% stake in Haleon, the UK consumer healthcare company, in a block trade on ...

Notable medicines subject to price increases include Pfizer’s COVID-19 drug Paxlovid, Bristol Myers Squibb’s CAR-T therapies Abecma and Breyanzi and a clutch of vaccines from Sanofi ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...

Pfizer targets $4 billion in operational savings by 2024, improving margins and driving long-term profitability. PFE returned $7.1 billion via dividends in 9M-24, while reducing debt by $4.4 ...

Strong performance in oncology and specialty products is fueling new growth at Pfizer. The stock's 6.3% dividend is well-funded, and management has just increased it. The bar is low for ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

In 1996, a pharmaceutical giant, Pfizer, administered a drug known as ... in to shoulder the burden of her school fees, feeding, clothing, and transportation. However, the emotional toll of ...

They even generated clinical results that suggested it might have promise as a weight-loss drug as well — only to have Pfizer, which had agreed to fund the research, withdraw its support ...

Pfizer's stock has underperformed, but management's focus on R&D and cost efficiencies should boost margins and free cash flow, supporting a Buy rating. Despite political headwinds, PFE's ...

Pfizer reiterated its forecast for 2024 and issued a new one for 2025. Management generally tried to calm some worries from rattled shareholders. There are still a couple of issues to be aware of ...